Posted by Michael Wonder on 05 Apr 2021
Supernus announces FDA approval of Qelbree (SPN-812) for the treatment of ADHD
2 April 2021 - Qelbree (viloxazine extended release capsules) represents the first novel non-stimulant treatment for ADHD in a decade.
Supernus Pharmaceuticals today announced that the U.S. FDA approved Qelbree (viloxazine extended release capsules) for the treatment of attention-deficit hyperactivity disorder in paediatric patients 6 to 17 years of age.
